Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer

Prostate

Volumn 75, Issue 9, 2015, Pages 957-968

  Ding, Guanxiong ^a   Fang, Jie ^a   Tong, Shijun ^a   Qu, Lianxi ^a   Jiang, Haowen ^a   Ding, Qiang ^a   Liu, Jun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

EMT; ERK; LCN2; prostate cancer; SLUG

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; FIBRONECTIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAI1; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 1,3 BUTADIENE DERIVATIVE; ACUTE PHASE PROTEIN; ENZYME INHIBITOR; LCN2 PROTEIN, HUMAN; LIPOCALIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRILE; ONCOPROTEIN; RNA; SNAIL FAMILY TRANSCRIPTION FACTORS;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO CULTURE; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CELL MOTION; CHEMISTRY; CYTOCHEMISTRY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ACUTE-PHASE PROTEINS; ANIMALS; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HETEROGRAFTS; HISTOCYTOCHEMISTRY; HUMANS; LIPOCALINS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NITRILES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRANSCRIPTION FACTORS;

EID: 84930010198     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22978     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A,. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-271.
3. Nandana S, Chung LW,. Prostate cancer progression and metastasis: Potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol 2014; 2: 92-101.
4. Steeg PS,. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.
5. Ye XC, Choueiri M, Tu SM, Lin SH,. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 2007; 12: 3273-3286.
6. Bahl A,. Metastatic castration-resistant prostate cancer. Part 1: The challenges of the disease and its treatment. Eur J Oncol Nurs 2013; 17 (Suppl 1): S1-S6.
7. Heemers HV, Mohler JL,. Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. Am J Clin Exp Urol 2014; 2: 121-126.
8. Aragon-Ching JB,. The evolution of prostate cancer therapy: Targeting the androgen receptor. Front Oncol 2014; 4: 295.
9. Galsky MD, Small AC, Tsao CK, Oh WK,. Clinical development of novel therapeutics for castration-resistant prostate AT historic challenges and recent successes. CA Cancer J Clin 2012; 62: 299-308.
10. Flower DR,. The lipocalin protein family: Structure and function. Biochem J 1996; 318 (Pt 1): 1-14.
11. Yan L, Borregaard N, Kjeldsen L, Moses MA,. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276: 37258-37265.
12. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N,. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-10432.
13. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J,. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002; 10: 1045-1056.
14. Yang J, Mori K, Li JY, Barasch J,. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003; 285: F9-F18.
15. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP,. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005; 391: 441-448.
16. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE,. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007; 120: 2426-2434.
17. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A, Vuttariello E, Chiappetta G, Formisano S, Leonardi A,. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA 2008; 105: 14058-14063.
18. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W,. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009; 89: 531-548.
19. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA,. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106: 3913-3918.
20. Yang J, Moses MA,. Lipocalin 2: A multifaceted modulator of human cancer. Cell Cycle 2009; 8: 2347-2352.
21. Kalluri R, Neilson EG,. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
22. Rastaldi MP,. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J Nephrol 2006; 19: 407-412.
23. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
24. Vernon AE, LaBonne C,. Tumor metastasis: A new twist on epithelial-mesenchymal transitions. Curr Biol 2004; 14: R719-R721.
25. Lee JM, Dedhar S, Kalluri R, Thompson EW,. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
26. Thiery JP, Acloque H, Huang RY, Nieto MA,. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
27. Luo Y, He DL, Ning L, Shen SL, Li L, Li X, Zhau HE, Chung LW,. Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 2006; 98: 1315-1319.
28. Nieto MA,. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-166.
29. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C,. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 2006; 25: 4975-4985.
30. Liu J, Uygur B, Zhang Z, Shao L, Romero D, Vary C, Ding Q, Wu WS,. Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate 2010; 70: 1768-1777.
31. Ding G, Feng C, Jiang H, Ding Q, Zhang L, Na R, Xu H, Liu J,. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition. PLoS ONE 2013; 8: e77400.
32. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T, Lobie PE,. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 2008; 149: 3909-3919.
33. Mimeault M, Batra SK,. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006; 27: 1-22.
34. Yang J, McNeish B, Butterfield C, Moses MA,. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 2013; 27: 45-50.
35. Li EM, Xu LY, Cai WJ, Xiong HQ, Shen ZY, Zeng Y,. Functions of neutrophil gelatinase-associated lipocalin in the esophageal carcinoma cell line SHEEC. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003; 35: 247-254.
36. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R,. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385.
37. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM,. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479-2488.
38. Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP,. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005; 280: 13641-13647.
39. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y,. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15: 195-206.
40. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X,. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153-5162.
41. Alberga A, Boulay JL, Kempe E, Dennefeld C, Haenlin M,. The snail gene required for mesoderm formation in Drosophila is expressed dynamically in derivatives of all three germ layers. Development 1991; 111: 983-992.
42. Uygur B, Wu WS,. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer 2011; 10: 139.
43. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P,. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006; 12: 5395-5402.
44. Tamura S, Shiozaki H, Miyata M, Kadowaki T, Inoue M, Matsui S, Iwazawa T, Takayama T, Takeichi M, Monden M,. Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg 1996; 83: 1608-1614.
45. Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, Sarbia M, Carneiro F, Becker KF,. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol 2007; 211: 507-515.
46. Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM,. Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: Implications for cell adhesion and signaling. Eur J Cancer 1999; 35: 60-65.
47. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S,. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005; 129: 1375-1383.
48. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG,. Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 2007; 13: 4769-4776.
49. Elloul S, Silins I, Trope CG, Benshushan A, Davidson B, Reich R,. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006; 449: 520-528.
50. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH,. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22: 153-183.
51. Lei YY, Wang WJ, Mei JH, Wang CL,. Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pac J Cancer Prev 2014; 15: 8539-8548.